Ovum SPF Raises €1.45M for Vaccine Ingredient Production

Navarre-based Ovum SPF has finalized a significant funding round totaling €1.45 million, crucial for completing the operational setup of its specialized biological product facility in Cascante. The financing received a substantial boost from Sodena, which provided a guarantee of €900,000, representing 60% of the total capital secured. This strategic infusion of funds is earmarked for the final stages of bringing the plant online, positioning Ovum SPF to become a key supplier in the vaccine manufacturing supply chain.

The comprehensive financial package also saw contributions from reciprocal guarantee societies Elkargi and Sonagar, alongside banking partner Bankinter. This collaborative effort underscores the confidence in Ovum SPF's mission to produce specific-pathogen-free (SPF) eggs, a vital component for vaccine development and research. The company's focus on high-value biological inputs aligns with the growing global demand for advanced biopharmaceutical manufacturing capabilities.

Ovum SPF has already commenced the initial dispatch of its biological products, signaling a critical milestone towards full-scale production, which is projected for 2027. The company's strategic location in Cascante, Navarre, taps into a region increasingly recognized for its industrial and technological development. This venture is particularly noteworthy within the biotechnology and pharmaceutical sectors, where reliable sourcing of high-quality biological materials is paramount.

Sodena, a consistent supporter of Ovum SPF since 2023, views this project as strategically important due to its industrial, technological, and health-related contributions. The agency's involvement, including a seat on the company's board, highlights its commitment to fostering innovation and economic growth within Navarre. The total investment to date has surpassed €8 million, with the promoter team demonstrating significant equity commitment, reflecting strong belief in the venture's long-term viability.

The facility has already generated 17 jobs during its initial operational phase, with plans to expand its workforce to 25 employees by the end of 2026. Ovum SPF is currently engaged in validation studies with pharmaceutical firms across Spain, France, Italy, the United States, and South America, preparing for scaled manufacturing. This international reach emphasizes the global demand for its specialized outputs and the company's ambition to be a significant player in the international vaccine ingredient market.

David Ayensa, representing the Ovum SPF promoter team, emphasized the pivotal role of Sodena and the participating financial institutions in navigating the final setup phase. He noted the plant's international outlook, technical sophistication, and its capacity to create skilled employment in Navarre. This development is set to bolster the region's industrial and biotechnological ecosystem, integrating a high-value activity into the global vaccine production network.